Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. [Review]

MedStar author(s):
Citation: Journal of the American Academy of Dermatology. 83(4):1150-1159, 2020 Oct.PMID: 32569797Institution: MedStar Washington Hospital CenterDepartment: DermatologyForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Coronavirus Infections/pc [Prevention & Control] | *Dermatology/st [Standards] | *Immunosuppression/st [Standards] | *Pandemics/pc [Prevention & Control] | *Pneumonia, Viral/pc [Prevention & Control] | *Practice Guidelines as Topic | *Skin Diseases/th [Therapy] | Advisory Committees/st [Standards] | Betacoronavirus/im [Immunology] | Betacoronavirus/py [Pathogenicity] | Clinical Decision-Making | Coronavirus Infections/ep [Epidemiology] | Coronavirus Infections/im [Immunology] | Coronavirus Infections/vi [Virology] | Decision Making, Shared | Dermatologists/st [Standards] | Dermatology/mt [Methods] | Disease Susceptibility/im [Immunology] | Hospitalists/st [Standards] | Humans | Immunosuppression/ae [Adverse Effects] | Immunosuppression/mt [Methods] | Interdisciplinary Communication | Pneumonia, Viral/ep [Epidemiology] | Pneumonia, Viral/im [Immunology] | Pneumonia, Viral/vi [Virology] | Skin Diseases/im [Immunology] | Societies, Medical/st [Standards] | Symptom Flare UpYear: 2020ISSN:
  • 0190-9622
Name of journal: Journal of the American Academy of DermatologyAbstract: Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19 outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Copyright (c) 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.All authors: Anadkat MJ, Chen ST, Fox LP, Harp J, Merola JF, Micheletti RG, Nambudiri VE, Niaki OZ, Pasieka HB, Rosenbach M, Shinohara MMOriginally published: Journal of the American Academy of Dermatology. 2020 Jun 19Fiscal year: FY2021Fiscal year of original publication: FY2020Digital Object Identifier: Date added to catalog: 2020-08-26
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32569797 Available 32569797

Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19 outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Copyright (c) 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

English

Powered by Koha